Other Events ·
The CHMP of the European Medicines Agency has recommended Datroway (datopotamab deruxtecan) for approval as a 1st-line…
AZNAstrazeneca PLC
The CHMP of the European Medicines Agency has recommended Datroway (datopotamab deruxtecan) for approval as a 1st-line treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy. Based on the TROPION-Breast02 Phase III trial, Datroway demonstrated a 5.0-month improvement in median overall survival (23.7 months vs 18.7 months) and a 43% reduction in the risk of disease progression or death. AstraZeneca and Daiichi Sankyo jointly develop and commercialize Datroway; the drug is already approved in the US and in HR-positive, HER2-negative breast cancer. AstraZeneca is a global, science-led biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals.